Ginkgo Bioworks Holdings Long Term Debt 2020-2022 | DNA

Ginkgo Bioworks Holdings long term debt from 2020 to 2022. Long term debt can be defined as the sum of all long term debt fields.
  • Ginkgo Bioworks Holdings long term debt for the quarter ending March 31, 2022 was $0.027B, a INF% increase year-over-year.
  • Ginkgo Bioworks Holdings long term debt for 2021 was $0.022B, a 34.9% increase from 2020.
  • Ginkgo Bioworks Holdings long term debt for 2020 was $0.017B, a INF% increase from 2019.
  • Ginkgo Bioworks Holdings long term debt for 2019 was $0B, a NAN% decline from .
Ginkgo Bioworks Holdings Annual Long Term Debt
(Millions of US $)
2021 $22
2020 $17
2019 $
Ginkgo Bioworks Holdings Quarterly Long Term Debt
(Millions of US $)
2022-03-31 $27
2021-12-31 $22
2021-09-30 $16
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.449B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.361B 9.79
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.336B 18.98
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Myovant Sciences (MYOV) United Kingdom $1.774B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.82
Zymeworks (ZYME) Canada $0.430B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.118B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00